Novo Nordisk offloads Parkinson’s cell therapy to focus on obesity and diabetes, with CagriSema pending US approval and oral semaglutide reaching 1M patients.

Novo Nordisk is accelerating its transformation into a pure-play metabolic powerhouse, offloading its clinical-stage Parkinson’s cell therapy program just as it awaits a pivotal US regulatory verdict on its next-generation obesity candidate CagriSema. The Danish drugmaker has handed global rights to STEM-PD over to Cellular Intelligence, retaining an equity stake and potential milestone payments in exchange for shedding development costs and operational risk. The move caps a broader reorganization that began last autumn, when Novo Nordisk shut down its entire cell therapy unit, cutting roughly 250 positions.

STEM-PD, a therapy that transforms donor stem cells into neurons for transplantation into Parkinson’s patients, had already earned a Fast-Track designation from the FDA and an IND clearance for human testing. Cellular Intelligence plans to apply its AI platform to speed up manufacturing and clinical development, with a Phase?2 study targeted by year-end. For Novo Nordisk, the deal follows a similar transaction in January, when Aspect Biosystems took over other stem?cell assets from the Novo portfolio. The company is now funneling capital and management bandwidth squarely into obesity and diabetes—the twin pillars that will determine its next chapter.

That focus is already bearing fruit with oral semaglutide, the tablet version of Wegovy. Since its launch at the start of 2026, the pill has been picked up by more than one million patients, according to CEO Mike Doustdar. In the US, Wegovy now accounts for 65?% of all new prescriptions in its class, helping Novo Nordisk hold onto a market share of roughly 55?% for weekly injectable GLP?1 products. That matters because the landscape has tilted increasingly toward Eli Lilly’s Zepbound, and Novo needs to defend its turf while also building the next growth engine.

That engine is CagriSema, a fixed-dose combination of semaglutide and the amylin analogue cagrilintide. In the REDEFINE?1 trial, CagriSema delivered a 22.7?% mean weight loss after 68 weeks, compared with 16.1?% for semaglutide alone. The company has already filed for US approval, with a decision expected in the fourth quarter of this year. A parallel cardiovascular outcomes study, REDEFINE?3, is underway with 7,000 participants. The pressure is high: earlier data disappointed because CagriSema failed to match Zepbound’s weight?reduction profile, and how regulators and clinicians view that comparison will shape the drug’s commercial reception.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Beyond CagriSema, Novo’s early-stage pipeline includes LX9851, an oral obesity candidate outside the incretin class that entered a phase?1 trial in March, with completion expected in the first quarter of 2027. The company is also working on multi?hormone agonists such as Amycretin and UBT251. In the first quarter of 2026 alone, it reported six regulatory approvals and more than ten new trial starts. Spending on R&D and marketing reached 22.4?billion Danish kroner, while a share?buyback program of up to 15?billion kroner is running through the year.

The quarterly numbers themselves painted a mixed picture. Revenue fell 10?% to 70.1?billion kroner on a currency?adjusted basis, and adjusted earnings per share slipped 3?%. Yet the market had braced for worse, and the company modestly raised its full?year guidance, now projecting a currency?adjusted decline in sales and operating profit of 4?% to 12?%—still a drop, but less steep than earlier forecasts.

Analysts are beginning to take notice. Citi lifted its price target on Novo Nordisk from 275 to 290 Danish kroner while holding a “Neutral” rating, citing moderate earnings upgrades starting in 2027. The bank is particularly bullish on oral Wegovy, projecting 2.7?billion dollars in sales in 2026 and a peak of 8?billion dollars—well above consensus. That bet hinges entirely on how quickly the oral GLP?1 market expands beyond early adopters.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

At current levels near 40?euros, Novo Nordisk shares trade at roughly 13.6 times expected earnings, a discount to the health?care sector average of about 16.8 times. The stock has recovered nearly 19?% over the past month, though it remains down roughly 11?% year?to?date—a reminder of how much value evaporated during two lean years that erased more than 60?% of the company’s market cap. The obesity market itself remains vast: more than 900?million people worldwide are living with obesity, yet only about 1?% currently receive brand?name pharmacotherapy.

With the Parkinson program now in other hands, Novo Nordisk has cleared another distraction from its books. The next concrete test for the recovery narrative comes in the fourth quarter, when the FDA weighs in on CagriSema. If that verdict aligns with the improving clinical data and the early traction of oral Wegovy, the stock’s recent rally may prove more than a temporary reprieve.

Ad

Novo Nordisk Stock: New Analysis – 14 May

Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis…